Moomoo AI 已提取核心信息
ZyVersa Therapeutics, Inc. has announced a special meeting of stockholders to be held virtually on April 17, 2024. The primary agenda is to seek approval for a reverse stock split of issued common stock at a ratio between 1-for-2 and 1-for-50, at the board's discretion, without further stockholder approval. This move aims to avoid delisting from Nasdaq, attract brokerage firms and investors, and facilitate future financings. The company also seeks approval to adjourn the meeting if necessary to solicit more votes for the reverse stock split. The record date for determining stockholders eligible to vote is March 5, 2024. The company encourages stockholders to vote by proxy prior to the meeting, with detailed voting instructions provided. The reverse stock split is intended as a recapitalization for tax purposes, with no gain or loss recognized by the company or stockholders. The board recommends voting 'FOR' both the reverse stock split and the potential adjournment.
ZyVersa Therapeutics, Inc. has announced a special meeting of stockholders to be held virtually on April 17, 2024. The primary agenda is to seek approval for a reverse stock split of issued common stock at a ratio between 1-for-2 and 1-for-50, at the board's discretion, without further stockholder approval. This move aims to avoid delisting from Nasdaq, attract brokerage firms and investors, and facilitate future financings. The company also seeks approval to adjourn the meeting if necessary to solicit more votes for the reverse stock split. The record date for determining stockholders eligible to vote is March 5, 2024. The company encourages stockholders to vote by proxy prior to the meeting, with detailed voting instructions provided. The reverse stock split is intended as a recapitalization for tax purposes, with no gain or loss recognized by the company or stockholders. The board recommends voting 'FOR' both the reverse stock split and the potential adjournment.
ZyVersa Therapeutics, Inc.已宣布将于2024年4月17日虚拟举行股东特别会议。主要议程是寻求批准以1比2和1比50的比例对已发行普通股进行反向分割，由董事会自行决定，无需进一步获得股东的批准。此举旨在避免从纳斯达克退市，吸引经纪公司和投资者，并促进未来的融资。如有必要，该公司还寻求批准休会，以争取更多反向股票拆分的选票。确定有资格投票的股东的记录日期是2024年3月5日。该公司鼓励股东在会议之前通过代理人进行投票，并提供详细的投票说明。反向股票拆分旨在出于税收目的进行资本重组，公司或股东不确认损益。董事会建议对反向股票拆分和可能的休会投赞成票。
ZyVersa Therapeutics, Inc.已宣布将于2024年4月17日虚拟举行股东特别会议。主要议程是寻求批准以1比2和1比50的比例对已发行普通股进行反向分割，由董事会自行决定，无需进一步获得股东的批准。此举旨在避免从纳斯达克退市，吸引经纪公司和投资者，并促进未来的融资。如有必要，该公司还寻求批准休会，以争取更多反向股票拆分的选票。确定有资格投票的股东的记录日期是2024年3月5日。该公司鼓励股东在会议之前通过代理人进行投票，并提供详细的投票说明。反向股票拆分旨在出于税收目的进行资本重组，公司或股东不确认损益。董事会建议对反向股票拆分和可能的休会投赞成票。
有用
没用